search
Back to results

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Primary Purpose

Neoplasm, Lymphomas, Neoplasm Metastasis

Status
Terminated
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
PEG-paclitaxel
Sponsored by
Enzon Pharmaceuticals, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neoplasm focused on measuring Phase I, Open label, Safety/efficacy, Lymphomas, Advanced primary and/or metastatic solid tumors, Neoplasms, Neoplasm metastasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

None - Study has been terminated.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    August 24, 2001
    Last Updated
    June 23, 2005
    Sponsor
    Enzon Pharmaceuticals, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00023166
    Brief Title
    Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
    Official Title
    Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2004
    Overall Recruitment Status
    Terminated
    Study Start Date
    May 2001 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    May 2002 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Enzon Pharmaceuticals, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    Studies of PEG-paclitaxel have been terminated

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Neoplasm, Lymphomas, Neoplasm Metastasis
    Keywords
    Phase I, Open label, Safety/efficacy, Lymphomas, Advanced primary and/or metastatic solid tumors, Neoplasms, Neoplasm metastasis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    PEG-paclitaxel

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    None - Study has been terminated.

    12. IPD Sharing Statement

    Learn more about this trial

    Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

    We'll reach out to this number within 24 hrs